Moricizine (HCl)

Drug #1551

Moricizine (HCl) is an oral class I antiarrhythmic agent, chemically unrelated to any other antiarrhythmic drugs. Classification of moricizine within the group of class I antiarrhythmics is difficult since the drug has features of all three subclasses, class Ia, Ib, and Ic. Although chemically related to phenothiazines, moricizine has no central or peripheral dopamine blocking activity.Moricizine (HCl) is reserved for the treatment of life-threatening ventricular arrhythmias. Moricizine was originally synthesized in the Soviet Union in 1964 and has been in use there since 1971. Moricizine was FDA approved on June 19, 1990. Moricizine (HCl) is currently only available as oral tablets.

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin and belongs to Phenothiazine Derivative.

Molecular Weight: 464 · Solubility in Water: freely · Solubility in Alcohol: soluble · Non-proprietary name: Moricizine (HCl).

Pharmacokinetics

Absorption: Moricizine (HCl) has an oral bioavailability is 47.5% (±47.5%), pre-systemic (first-pass) metabolism accounts for 64% (±2%).

Distribution: Moricizine (HCl) has a volume of distribution is 8.3 - 11.1 l/Kg. plasma protein binding is 81-95%.

Elimination: plasma half-life is 2.5 hr, renal excretion is 39% (0.05% unchanged).

Indications

Moricizine (HCl) is primarily indicated in conditions like Atrial arrhythmias, Ventricular arrhythmias.

Contraindications

Moricizine (HCl) is contraindicated in conditions like Cardiogenic shock, Sick sinus syndrome, Second or third degree A-V block, Hypersensitivity.

Dosage

Moricizine (HCl)'s dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
750 mg	750 mg	Every 3h	Oral	Daily in 3 divided doses adjusted by steps of 150mg daily at intervals of 3 drops.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

Unknown3 interactions

1 interaction

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Moricizine (HCl) in overdosage may give rise to further complications which include Respiratory depression , Seizures , Sinus bradycardia .

Moricizine (HCl) produces potentially life-threatening effects which include Ventricular arrhythmias, Pro-arrhythmiagenicity, Elevated creatine phosphokinase ESR. Careful monitoring is needed with proper medical management.

The signs and symptoms that are produced after acute overdosage of Moricizine (HCl) are Cardiac arrhythmias.

Moricizine (HCl) is known to cause more or less tolerable side effects which are usually transient. These include Abdominal pain, Anxiety, Blurred vision, Confusion, Constipation , Diarrhea, Dizziness, Drowsiness, Dry mouth, Dyspepsia , Dyspnea, Fatigue, Fever, Headache, Musculoskeletal pain , Nausea, Palpitation, Paresthesias, Postural dizziness, Restlessness, Sleep disturbance, Tremor, Vomiting , Weakness.

Warnings / Precautions

Electrolyte imbalance should be corrected before initiating therapy. It should be used with caution in patients with pace makers, with pronounced hepatic function, with G6PD deficiency. Reduction in dosage may be necessary in patients with impaired renal function. Topically it should be used with caution in patients with hepatic disease or impairent. It is classified as category B for use during pregnancy. It should be used only when clearly needed during pregnancy.

Available Brands

None recorded.

Storage Conditions

Moricizine (HCl) should be stored Tab .

Drug Classification

1.12.2 — Antiarrhythmic drugs